Log in to save to my catalogue

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammat...

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammat...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2715443238

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

About this item

Full title

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

Journal title

Annals of the rheumatic diseases, 2023-02, Vol.82 (2), p.292-300

Language

English

Formats

Publication information

Publisher

England: BMJ Publishing Group Ltd and European League Against Rheumatism

More information

Scope and Contents

Contents

ObjectivesA third COVID-19 vaccination is recommended for immunosuppressed patients. However, data on immunogenicity and safety of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases (IMIDs) are sparse and therefore addressed within this clinical trial.Methods60 immunosuppressed patients and 48 healthy controls (HCs)...

Alternative Titles

Full title

Safety and immunogenicity of a third COVID-19 vaccination in patients with immune-mediated inflammatory diseases compared with healthy controls

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2715443238

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2715443238

Other Identifiers

ISSN

0003-4967

E-ISSN

1468-2060

DOI

10.1136/ard-2022-222682

How to access this item